| Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma JM Janssen, N de Vries, N Venekamp, H Rosing, ADR Huitema, ... Journal of Pharmaceutical and Biomedical Analysis 174, 561-566, 2019 | 45 | 2019 |
| Exposure–response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non‐small cell lung cancer patients SL Groenland, DR Geel, JM Janssen, N de Vries, H Rosing, JH Beijnen, ... Clinical Pharmacology & Therapeutics 109 (2), 394-402, 2021 | 36 | 2021 |
| Therapeutic drug monitoring of gentamicin peak concentrations in critically ill patients CJ Hodiamont, JM Janssen, MD de Jong, RA Mathôt, NP Juffermans, ... Therapeutic drug monitoring 39 (5), 522-530, 2017 | 24 | 2017 |
| Pharmacokinetic targets for therapeutic drug monitoring of small molecule kinase inhibitors in pediatric oncology JM Janssen, TPC Dorlo, N Steeghs, JH Beijnen, LM Hanff, ... Clinical Pharmacology & Therapeutics 108 (3), 494-505, 2020 | 19 | 2020 |
| Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs JM Janssen, TPC Dorlo, JH Beijnen, ADR Huitema Therapeutic Drug Monitoring 42 (4), 532-539, 2020 | 16 | 2020 |
| Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real‐world cohort study: does age matter? MRBS Crombag, JGC van Doremalen, JM Janssen, H Rosing, ... British journal of clinical pharmacology 84 (12), 2770-2778, 2018 | 16 | 2018 |
| Population pharmacokinetics of docetaxel, paclitaxel, doxorubicin and epirubicin in pregnant women with cancer: a study from the international network of cancer, infertility … JM Janssen, K Van Calsteren, TPC Dorlo, MJ Halaska, R Fruscio, ... Clinical Pharmacokinetics 60, 775-784, 2021 | 15 | 2021 |
| ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study MAC Vermunt, DGJ Robbrecht, LA Devriese, JM Janssen, B Thijssen, ... Cancer Reports 4 (4), e1367, 2021 | 10 | 2021 |
| Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer JM Janssen, RB Verheijen, TT van Duijl, L Lin, MM van den Heuvel, ... Clinical and Translational Science 15 (8), 1916-1925, 2022 | 9 | 2022 |
| Exploring episodic and semantic contributions to past and future thinking performance in Korsakoff’s syndrome J Janssen, E Oudman, M Irish, A Postma Memory & Cognition 50 (3), 630-640, 2022 | 8 | 2022 |
| A population pharmacokinetic model of oral docetaxel coadministered with ritonavir to support early clinical development H Yu, JM Janssen, E Sawicki, JGC van Hasselt, VA de Weger, B Nuijen, ... The Journal of Clinical Pharmacology 60 (3), 340-350, 2020 | 8 | 2020 |
| Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors RB Verheijen, TT Van Duijl, MM Van den Heuvel, D Vessies, M Muller, ... Cancer Chemotherapy and Pharmacology 87, 269-276, 2021 | 7 | 2021 |
| 567P Exposure-response analyses of dabrafenib and trametinib in melanoma patients SL Groenland, JM Janssen, C Nijenhuis, N de Vries, H Rosing, ... Annals of Oncology 31, S486-S487, 2020 | 6 | 2020 |
| Population pharmacokinetics of intracellular 5-fluorouridine 5′-triphosphate and its relationship with hand-and-foot syndrome in patients treated with capecitabine JM Janssen, BAW Jacobs, J Roosendaal, EJB Derissen, S Marchetti, ... The AAPS Journal 23, 1-9, 2021 | 5 | 2021 |
| Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium JM Janssen, CM Zwaan, JHM Schellens, JH Beijnen, ADR Huitema European Journal of Cancer 85, 78-85, 2017 | 5 | 2017 |
| Effect of food on the pharmacokinetics of the oral docetaxel tablet formulation ModraDoc006 combined with ritonavir (ModraDoc006/r) in patients with advanced solid tumours MAC Vermunt, VA de Weger, JM Janssen, MI Lopez-Yurda, M Keessen, ... Drugs in R&D 21, 103-111, 2021 | 3 | 2021 |
| A semi-mechanistic population pharmacokinetic/pharmacodynamic model of bortezomib in pediatric patients with relapsed/refractory acute lymphoblastic leukemia JM Janssen, TPC Dorlo, D Niewerth, AJ Wilhelm, CM Zwaan, JH Beijnen, ... Clinical pharmacokinetics 59, 207-216, 2020 | 3 | 2020 |
| Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients SL Groenland, DR Geel, JM Janssen, JH Beijnen, SA Burgers, EF Smit, ... Annals of Oncology 30, v608, 2019 | 3 | 2019 |
| Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS … A Rubio-San-Simón, NKA van Eijkelenburg, R Hoogendijk, H Hasle, ... Pediatric Drugs 25 (6), 719-728, 2023 | 2 | 2023 |
| Exposure–response analyses of BRAF-and MEK-inhibitors dabrafenib plus trametinib in melanoma patients SL Groenland, JM Janssen, CM Nijenhuis, N de Vries, H Rosing, ... Cancer Chemotherapy and Pharmacology 91 (6), 447-456, 2023 | 2 | 2023 |
